Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015, Please find enclosed herewith extracts of the standalone and consolidated unaudited financial results for the Third quarter and Nine months ended December 31, 2023 as published in the Financial express in the english language in all editions and gujarati language in Ahmedabad editions. kindly take the same above in your record purpose.
10-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to the provision of Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated January 31, 2024 to the Stock exchanges regarding Earning call in respect of the Unaudited (Standalone and Consolidated) Financial Results of the company for the Third Quarter and Nine Months ended December 31, 2023, we wish to inform that the said Earning Call was held today at 02:00 PM (IST). The audio recording of the conference call has been hosted on the website of the company and link to access the said recording is as follows: - Link :- https://www.concordbiotech.com/public/assets/pdf/q3fy24-earnings-audio-20240209175243.mp3 Kindly take the above on records.
09-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of Schedule III Part A of SEBI (LODR) Regulations, 2015, "investors presentation" on the financial results for the Third Quarter and Nine months ended December 31, 2023 is enclosed.
09-02-2024
Bigul

Concord Biotech Ltd - 543960 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E Thursday, February 08, 2024- Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2023

 Dear Sir/ Ma'am, With reference to the intimation of Board meeting submitted on January 30, 2024, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Thursday, February 08, 2024, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended December 31, 2023. The said results were also reviewed by the Audit Committee of the Company in its meeting held on February 08, 2024. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended December 31, 2023, along with the Limited Review Report of the Statutory auditors
08-02-2024
Bigul

Concord Biotech Ltd - 543960 - Unaudited Standalone And Consolidated Financial Results For The Third Quarter And Nine Months Ended December 31, 2023

 with reference to the intimation of Board meeting submitted on January 30, 2024, we would like inform you that the Board of Directors of the company , at its meeting held today i.e. Thursday, February 08, 2024, has inter-alia approved unaudited standalone and consolidated financial results for the third quarter and nine months ended on December 31, 2023.
08-02-2024
Bigul

Concord Biotech Ltd - 543960 - Intimation About Completion Of Inspection By Brazilian Health Regulatory Agency (ANVISA) At Dholka Facility (Unit I) Of The Company

 In Compliance with the aforesaid regulations, we hereby notify that Brazilian Health Regulatory Agency (ANVISA) has conducted inspection of our Unit 1 (API facility) of the company, located at Trasad Road, Dholka- 382225 in Ahmedabad. Gujarat from Monday, January 29, 2024 to Thursday, February 01, 2024. The said inspection has been completed successfully, without any adverse remarks.
01-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the unaudited (Standalone and Consolidated) Financial Results of the Company for the Third quarter and Nine months ended 31 December, 2023, scheduled on Friday, 9th February, 2024 at 02:00 P.M. IST. The Earnings Call invite is enclosed for your records. The conference/Earning Call Invitation is enclosed herewith. Kindly take the same into your records and oblige.
31-01-2024
Bigul

Concord Biotech Ltd - 543960 - Board Meeting Intimation for To Consider And Approve The Standalone And Consolidated Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2023

 Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the third quarter and Nine months ended December 31, 2023 along with limited review report to be issued by the Statutory Auditors and to consider other business matters, if any. Further, in continuation of our earlier letter dated December 29, 2023 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and their immediate relative, the trading window for dealing in the securities of the Company shall remain closed up to 48 hours after the declaration of the Financial Results of the Company for the third quarter and Nine months ended December 31, 2023. You are requested to take the same on record.
30-01-2024
Bigul

Concord Biotech Ltd - 543960 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 in Compliance with Reg. 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as amended from time to time, we furnish herewith certificate dated January 06, 2024, issued by Linkintime India Private Limited, Registrar and transfer agent of the company for the quarter ended December 31, 2023
08-01-2024

Choice Broking initiates coverage on Concord Biotech with Outperform' rating; sees 16% upside

 Concord Biotech has over the years built a portfolio of 23 fermentation APIs, scaled manufacturing capabilities and backwardly integrated its API to KSM creating a competitive edge in the industry.
02-01-2024
Next Page
Close

Let's Open Free Demat Account